34th week of 2018 patent applcation highlights part 10 |
Patent application number | Title | Published |
20180236041 | METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION - A method of treating a subject having or at risk for having a virus infection, by administering a therapeutically effective amount of a composition comprising a vector encoding a CRISPR-associated endonuclease and at least two guide RNAs that are complementary to two target sequences spanning from the 5′- to 3′-LTRs of the sequence in the virus, and completely excising a fragment of greater than 9000-bp of integrated proviral DNA that spanned from its 5′- to 3′-LTRs. A method of treating a subject having or at risk for having a genetic caused disease, by administering a therapeutically effective amount of a composition comprising a vector encoding a CRISPR-associated endonuclease and at least two guide RNAs that are complementary to two target sequences spanning from the sequence of the subjects DNA greater than 9000-bp that is chromosomally integrated and causes the genetic caused disease, and excising the chromosomally integrated sequence. | 2018-08-23 |
20180236042 | METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION - A method of treating a subject at risk for having a virus infection, by administering to the subject a prophylactically effective amount of a composition comprising a vector encoding a CRISPR-associated endonuclease and at least two guide RNAs, wherein the guide RNAs are complementary to two target sequences spanning from the 5′- to 3′-LTRs of the sequence in the virus, and preventing a retroviral infection. | 2018-08-23 |
20180236043 | METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION - A method of treating a subject having or at risk for having a virus infection, by administering to the subject a therapeutically effective amount of a composition comprising a vector encoding a CRISPR-associated endonuclease and at least two guide RNAs, wherein the guide RNAs are complementary to two target sequences spanning from the 5′- to 3′-LTRs of the sequence in the virus. A method of treating a subject having or at risk for having a virus infection, by administering to the subject a therapeutically effective amount of a composition comprising a vector encoding a CRISPR-associated endonuclease and at least two guide RNAs, wherein the guide RNAs are complementary to two target sequences spanning from the 5′- to 3′-LTRs of the sequence in the virus, and causing neither genotoxicity nor off-target editing to the host. | 2018-08-23 |
20180236044 | METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION - A personalized method of inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus, by determining a nucleic acid sequence of the proviral DNA harbored by a subject, designing two or more different guide RNAs (gRNAs) complementary to the proviral DNA sequences in the subject, treating the subject's host cells with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of the proviral DNA, and inactivating the proviral DNA. | 2018-08-23 |
20180236045 | METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION - A method of preventing transmission of a retrovirus from a mother to her offspring, by treating the mother's host cells with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of the proviral DNA, and preventing transmission of the proviral DNA to the offspring. | 2018-08-23 |
20180236046 | METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION - A composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus including an isolated nucleic acid encoding a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, an isolated nucleic acid sequence encoding a first guide RNA (gRNA) having a first spacer sequence that is complementary to a first target protospacer sequence in a proviral DNA, and an isolated nucleic acid sequence encoding a second gRNA having a second spacer sequence that is complementary to a second target protospacer sequence in the proviral DNA, wherein said first target protospacer sequence and said second target protospacer sequence are situated in a long terminal repeat (LTR) of the proviral DNA. A pharmaceutical composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus. | 2018-08-23 |
20180236047 | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES - Compositions for modulating the expression of a protein in a target cell comprising at least one RNA molecule which comprises at least one modification | 2018-08-23 |
20180236048 | SUBCUTANEOUS THERAPEUTIC ENZYME FORMULATIONS, USES, AND METHODS FOR GENERATING THEREOF - Provided herein are compositions containing a lysosomal storage disorder replacement enzyme (LSDRE) and a dispersing agent for subcutaneous injection for treatment of lysosomal storage diseases. Kits and methods of treatment are also provided. | 2018-08-23 |
20180236049 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME - The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor. | 2018-08-23 |
20180236050 | METHOD OF TREATING DEPRESSION - Methods are disclosed herein for treating depression in the subject. A method includes the use of Botulinum toxin to cause paralysis of a facial muscle, such as the depressor anguli oris, procerus, frontalis, orbicularis oculi, or corrugator supercilii muscle to treat depression in the subject. | 2018-08-23 |
20180236051 | METHOD FOR PRODUCING EMBRYONIC-LIKE STEM CELLS FROM TICKS (ACARI: IXODIDAE), COMPOSITION, USES THEREOF AND DIAGNOSTIC METHODS - The invention refers to a process for the production of a continuous cell line of simile embryo stem cells, such as Amblyomma sculptum (Acari: Ixodidae), known as line IBU/ASE-16 (access number with CNCM: 1-5000) and its uses. More specifically, the invention refers to a process for the production of the line IBU/ASE-16 and their use for obtaining extracts for the production of vaccines and candidate recombinant proteins for biopharmaceuticals and acaricides, production of diagnostic kits for the detection of antigens and/or antibodies for animal and human use, obtaining clones for use in genotyping and use as a substrate for the isolation and culture of pathogens. | 2018-08-23 |
20180236052 | DNA Vaccines Encoding Heat Shock Proteins - A method of treating a T cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 90 (HSP 90), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences. The disease is other than insulin dependent diabetes mellitus (IDDM) or rheumatoid arthritis. The administering of the immunogenic composition results in a shift of the immune response to a Th2 response, thereby treating the disease. | 2018-08-23 |
20180236053 | CELLS FOR IMMUNOTHERAPY ENGINEERED FOR TARGETING CD38 ANTIGEN AND FOR CD38 GENE INACTIVATION - Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said CD38 immune by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute. | 2018-08-23 |
20180236054 | Tetanus Toxoid and CCL3 Improve DC Vaccines - Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4 | 2018-08-23 |
20180236055 | VACCINE FOR INTRAUTERINE DISEASE - Provided are compositions and methods for use in prophylaxis of puerperal metritis and improving reproductive function of ruminants. The methods and compositions are for subcutaneous administration and are provided as veterinary compositions and as articles of manufacture. The veterinary composition can contain whole cells selected from whole cells of | 2018-08-23 |
20180236056 | Needle-free administration of PRRSV vaccines - The invention provides novel methods and compositions for the vaccination of porcine animals against porcine reproductive and respiratory syndrome virus (PRRSV). Described herein are immunological and/or vaccine compositions comprising a DNA vector encoding a PRRSV protein, particularly a truncated ORF7 protein, which are administered to porcines using needle-free delivery. The plasmid can include more than one nucleic acid molecule such that the plasmid can express more than one antigen. Also disclosed are methods for using and kits employing such compositions. | 2018-08-23 |
20180236057 | USE OF A PCV2 IMMUNOGENIC COMPOSITION FOR LESSENING CLINICAL SYMPTOMS IN PIGS - The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections. | 2018-08-23 |
20180236058 | REVERSE GENETICS SYSTEMS - The invention provides various reverse genetics systems for producing segmented RNA viruses, wherein the systems do not require bacteria for propagation of all of their expression constructs. | 2018-08-23 |
20180236059 | POLYSACCHARIDE COMPOSITION AND USE THEREOF - The present invention relates to the field of food or health care product, in particular a polysaccharide composition and use thereof. In the present invention, lentinan, pachymaran and tremellan are compounded. The resultant composition can significantly improve the survival rate and quality of life of mice infected by influenza virus, improve the pulmonary inflammatory lesion degree in mice infected by influenza virus, significantly improve levels of specific antibodies in serum of mice infected by influenza virus, significantly decrease the virus content in the lung of mice infected by influenza virus, as well as improve levels of cytokines IL-2 and IL-5 in the lung. In comparison with existing vaccines or single polysaccharides, the polysaccharide composition as provided in the present invention has more significant protective effects on mice infected by influenza virus. | 2018-08-23 |
20180236060 | HUMAN ROTAVIRUS VACCINE STRAINS AND DIAGNOSTICS - A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine. | 2018-08-23 |
20180236061 | AVIAN REOVIRUS VACCINES - The present invention relates to novel strains of avian reovirus that were isolated from clinical cases of viral arthritis/tenosynovitis in chickens in the southeast United States. The invention is directed to these novel group 1 and group 2 avian reoviruses, diagnostic assays using antibodies and/or nucleotide- or amino acid-specific components of such viruses, such as the S1 gene encoding the sigma C protein, and to vaccines that protect chickens from disease caused by such viruses. | 2018-08-23 |
20180236062 | USE OF INACTIVATED NONREPLICATING MODIFIED VACCINIA VIRUS ANKARA (MVA) AS MONOIMMUNOTHERAPY OR IN COMBINATION WITH IMMUME CHECKPOINT BLOCKING AGENTS FOR SOLID TUMORS - The present disclosure relates to infection-competent, but nonreplicative inactivated modified vaccinia Ankara (MVA) and its use as immunotherapy, alone, or in combination with immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to inducing an immune response in a subject diagnosed with a solid malignant tumor. | 2018-08-23 |
20180236063 | METHODS OF USING A VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT - Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glycopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier. | 2018-08-23 |
20180236064 | TARGETING TGR5 TO TREAT DISEASE - Materials and methods for treating cholangiopathies by targeting TGR5, including materials and methods for treating cholangiopathies such as polycystic liver disease, are provided herein. | 2018-08-23 |
20180236065 | COILED-COIL CONNECTOR - A connector of a helical coiled coil-type structure connecting a first and a second molecule, wherein the first molecule comprises a peptidic first alpha-helix and the second molecule comprises a peptidic second alpha-helix, which second alpha-helix is coiled to the first alpha-helix. The first alpha-helix comprises a C-terminal region consisting of a repeat of an amino acid motif a-x | 2018-08-23 |
20180236066 | METHODS OF TREATING CANCER USING PD-L1 AXIS BINDING ANTAGONISTS AND VEGF ANTAGONISTS - The present invention describes combination treatment comprising a PD-1 axis binding antagonist, chemotherapy and optionally a VEGF antagonist and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer. | 2018-08-23 |
20180236067 | Combination Of The Application Of Antibodies For Immunostimulation Together With Glucocorticoids - The present invention relates to methods for reducing or eliminating the non-specific release of a cytokine associated with a disease comprising administering at least one glucocorticoid and an immunostimulating antibody. Additionally, the present invention relates to a pharmaceutical composition that contains at least one immunostimulating antibody and at least one glucocorticoid. | 2018-08-23 |
20180236068 | THERAPEUTIC AGENTS FOR PANCREATIC CANCER - We achieved the present invention on the basis of the finding that an excellent therapeutic effect against pancreatic cancer can be obtained by administering an IL-6 inhibitor and an antimetabolite to pancreatic cancer patients. We also found that metastatic lesions from human pancreatic cancer can be reduced and ascites can be eliminated. | 2018-08-23 |
20180236069 | Methods for treating and/or limiting development of diabetes in subjects with amyotrophic lateral sclerosis - Methods for treating and/or limiting development of diabetes in a subject with amyotrophic lateral sclerosis (ALS) by inhibiting IgG-mediated activation of voltage-gated calcium channels (VGCCs) in cells of the subject, by one or more of removing IgG from blood of the subject, blocking IgG from activating VGCCs in the subject; or blocking VGCCs in the subject are described, as are methods for identifying ALS patients at risk of developing diabetes. | 2018-08-23 |
20180236070 | METHODS AND COMPOSITIONS COMPRISING A COMBINATION OF A VEGF ANTAGONIST AND AN ANTI-CTLA-4 ANTIBODY - The present invention provides pharmaceutical compositions comprising a VEGF antagonist and an anti-CTLA-4 antibody, and methods of use thereof. The compositions and methods of the present invention are useful for the treatment of cancers and other diseases and disorders in which anti-angiogenic therapies and/or targeted immune responses may be beneficial. | 2018-08-23 |
20180236071 | NOVEL ANTI-HUMAN GPVI ANTIBODIES AND USES THEREOF - The present invention relates to humanized anti-human GPVI antibodies and uses thereof. | 2018-08-23 |
20180236072 | EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS - The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab. | 2018-08-23 |
20180236073 | Methods and Compositions for Improving Antiangiogenic Therapy with Anti-Integrins - Described here are methods and compositions for treating tumors and metastases that improve anti-angiogenesis therapy. By inhibiting these mechanisms in a biological system with an anti-beta one integrin composition in combination with an antiangiogenic composition, tumors and metastases may be deprived of an adequate blood supply, thereby resulting in tumor cell growth arrest and possibly regression, including tumor cell death. The present compositions comprise an anti-beta one integrin agent in combination with an anti-VEGF agent, in a pharmaceutical composition or compositions. Methods of treatment and of imaging are also described. | 2018-08-23 |
20180236074 | THERMORESPONSIVE BIOCONJUGATES AND THEIR CONTROLLED DELIVERY OF CARGO - The present invention provides a bioconjugate. The bioconjugate comprises a first molecule comprising an elast-in-like peptide (ELP), a second molecule capable of self-associating into an oligomer, and a linker connecting the first molecule with the second molecule. The bioconjugate is self-assembled into particles, which are disassembled when the temperature is increased. Also provided is a method for delivering a bioconjugate to a target matrix, comprising (a) introducing a bioconjugate self-assembled into particles to a target matrix, wherein the bioconjugate comprises a first molecule comprising an elastin-like peptide (ELP), a second molecule capable of self-associating into an oligomer, and a linker connecting the first molecule with the second molecule, and (b) increasing the temperature of the target matrix to disassemble the particles at the target matrix. | 2018-08-23 |
20180236075 | ACOUSTIC DRIVEN DRUG DELIVERY SYSTEMS - The present invention provides acoustically activated liposome compositions for use as drug delivery vehicles, and to methods for drug release and drug delivery for therapeutic applications. | 2018-08-23 |
20180236076 | NEAR INFRARED PHOTOIMMUNOTHERAPY (NIR-PIT) OF SUPPRESSOR CELLS TO TREAT CANCER - It is shown that CD25-targeted near-infrared photo-immunotherapy causes a unique, rapid and spatially selective depletion of Tregs leading to regression of the treated tumor and inducing systemic immunologic responses in untreated tumors. Based on these observations, provided are compositions and methods of killing immune suppressor cells, for example to treat cancer. Reducing the number of suppressor cells in a subject can remove suppression of effector T cells, for example, to treat cancer using the subject's own immune system. In particular examples, the method includes contacting suppressor cells having a suppressor cell surface protein with an antibody-IR700 molecule, wherein the antibody specifically binds to the suppressor cell surface protein, and in some examples the antibody does not have a functional Fc region. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm, for example at a dose of at least 4 J cm | 2018-08-23 |
20180236077 | FORMULATIONS FOR EYE TREATMENTS - Formulations, are used for eye treatments, e.g., cross-linking treatments. For example, a therapeutic formulation includes a photosensitizer and delivery agent(s), wherein the delivery agent(s) include at least one of: anesthetic agent(s), analgesic agent(s), tonicity agent(s), or shear-thinning, or viscosity-increasing agent(s). In another example, a method includes applying preparatory formulation(s) to increase a permeability of a corneal epithelium, and applying therapeutic formulation(s) to the epithelium, where the preparatory formulation(s) include zinc metalloproteinase, copper metalloproteinase, papain, bromelain, actinidin, ficain, N-acetylcysteine, ambroxol, carbocisteine, and/or erdosteine. In yet another example, a method includes applying therapeutic formulation(s) to a corneal epithelium to deliver the therapeutic formulation(s) to a stroma, and applying enhancement formulation(s) to the epithelium in response to applying the therapeutic formulation(s), where: the enhancement formulation(s) remove the therapeutic formulation(s) from the epithelium; close tight junctions of the epithelium; promote oxidation for the therapeutic agent(s); and/or further deliver the therapeutic formulation(s) to the stroma. | 2018-08-23 |
20180236078 | Compositions with a Rheological Modifier to Reduce Dissolution Variability - The present disclosure provides compositions (e.g., extended release compositions) which exhibit a desirable pharmacokinetic profile of an active agent while providing reduced dissolution sample variability, e.g., in the form of reduced inter-capsule variability and/or a reduction in storage-time dependent change in mean release of the active agent from the composition. Related methods of making and administering the disclosed compositions and formulations are also provided. | 2018-08-23 |
20180236079 | STABILIZED GLUCAGON SOLUTIONS - This invention relates to ready-to-use and safe solution compositions of glucagon suitable for administration by manual injection or by an insulin pump or other injection device to treat hypoglycemia. Said compositions comprise glucagon, an acid, anti-gelling polyol, a stabilizing-salt, viscosity reducer and an antioxidant, have a final pH between about 2 and 5, and is gel-free, chemically-stable, and pump-able. | 2018-08-23 |
20180236080 | FAST-ACTING INSULIN COMPOSITION COMPRISING A CITRIC ACID SALT - In embodiments, the present disclosure provides an aqueous pharmaceutical composition that includes insulin in hexameric form, and citric acid or a salt thereof at a concentration from 6 to 30 mM, wherein the composition is suitable for injecting into a diabetic patient to treat diabetes. | 2018-08-23 |
20180236081 | DELIVERY OF NEGATIVELY CHARGED PROTEINS USING CATIONIC LIPIDS - Compositions, methods, strategies, kits, and systems for the delivery of negatively charged proteins, protein complexes, and fusion proteins, using cationic polymers or lipids are provided. Delivery of proteins into cells can be effected in vivo, ex vivo, or in vitro. Proteins that can be delivered using the compositions, methods, strategies, kits, and systems provided herein include, without limitation, enzymes, transcription factors, genome editing proteins, Cas9 proteins, TALEs, TALENs, nucleases, binding proteins (e.g., ligands, receptors, antibodies, antibody fragments; nucleic acid binding proteins, etc.), structural proteins, and therapeutic proteins (e.g., tumor suppressor proteins, therapeutic enzymes, growth factors, growth factor receptors, transcription factors, proteases, etc.), as well as variants and fusions of such proteins. | 2018-08-23 |
20180236082 | PERCUTANEOUS ABSORPTION COMPOSITION - The embodiments provide a percutaneous absorption composition for a basic medicament having improved transdermal absorbability. The percutaneous absorption composition comprises a sorbic acid and/or a metal sorbate as a percutaneous absorption promotor. The molar ration of the sorbic acid and/or the metal sorbate to the basic medicament is 0.5-2.5. The composition of the present disclosure may further comprise a basic component. | 2018-08-23 |
20180236083 | HYDRATED FOOD - Providing a hydrated food which contains theanine and in which theanine content can stably be maintained even when the hydrated food is preserved for a long period of time and the taste threshold of the food can be improved and the peculiar taste can be flavored. The problem can be overcome by a hydrated food containing theanine and pyroglutamic acid. In this case, it is preferable that pH ranges from about 2.8 to about 7.5. Furthermore, it is preferable that a content of pyroglutamic acid ranges from about 1% to about 20% relative to a content of theanine. | 2018-08-23 |
20180236084 | Method for Enhancing Specific Immunotherapies in Cancer Treatment - Methods and compositions of the invention relate to the enhancement of specific immunotherapies in cancer treatment. In particular, aspects of the invention relate to novel approaches to boost immune function using a complex carbohydrate pharmaceutical compound alone or in combination with other targeted immunotherapy to increase the efficacy of immunotherapy of cancer. | 2018-08-23 |
20180236085 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN THE ISOELECTRIC POINT OF WHICH IS COMPRISED IN 5.8 AND 8.5 AND AN ANIONIC COMPOUND BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS - A composition in the form of an injectable aqueous solution, the pH of which is from 6.6 to 7.8, comprises at least:
| 2018-08-23 |
20180236086 | SYSTEM FOR ADMINISTERING BIOLOGICALLY ACTIVE SUBSTANCES PRODUCED BY FOAMING TECHNIQUES USING COMPRESSED GASES OR SUPERCRITICAL FLUIDS - A system for administering biologically active substances produced by foaming techniques using compressed gases or supercritical fluids relates to a porous system containing biologically active substances. The system includes a polymer matrix of poly(D,L-lactic-co-glycolic acid) or a polymer mixture containing poly(D,L-lactic-co-glycolic acid) of an intrinsic viscosity of less than 0.5 dL/g with other biodegradable synthetic or semisynthetic polyesters, a release-regulating component (starch and derivatives), and at least one biologically active substance. The matrix is biodegradable with a solid or semisolid consistency and a homogeneous appearance. A method for producing these systems using foaming with compressed fluids, and the use for the production of implants and scaffolds having this system are also disclosed. Optionally, a porogenic agent can be used for the formation of macropores by thermal decomposition. | 2018-08-23 |
20180236087 | EMULSIONS OR MICROEMULSIONS FOR USE IN ENDOSCOPIC MUCOSAL RESECTIONING AND/OR ENDOSCOPIC SUBMUCOSAL DISSECTION - The present invention relates to a pharmaceutical composition in form of emulsion or microemulsion and the use thereof as aid during endoscopic procedures in which it is injected in a target tissue in order to form a cushion. More in details, the invention relates to a method for performing an endoscopic procedure, which comprises injecting said pharmaceutical composition in form of emulsion or microemulsion in a target tissue of a patient, in order to form a cushion, which cushion is then optionally subjected to an endoscopic surgical procedure, such as a resection. | 2018-08-23 |
20180236088 | COMPOSITION FOR SKIN PERMEATION COMPRISING CATIONIC MOLECULAR TRANSPORTER AND PROTEIN - The present invention relates to a composition for skin permeation to deliver a protein into skin, wherein the composition comprises an ionic conjugate in which a cationic compound and a protein are ionically bound. As the ionic conjugate according to the present invention allows the protein to easily pass through cell membranes and skin membranes, it is possible to deliver the protein to an epidermal or dermal layer of the skin. | 2018-08-23 |
20180236089 | RADIATION EMITTING PEPTIDE NUCLEIC ACID CONJUGATES AND USES THEREOF FOR DIAGNOSIS, IMAGING, AND TREATMENT OF DISEASES, CONDITIONS AND DISORDERS - Provided is a conjugate including at least one radiation emitting probe and at least one gene complementary component for use in highly sensitive diagnosis, imaging, and treatment of conditions, diseases and disorders, including compositions including said conjugates and kits thereof. | 2018-08-23 |
20180236090 | COMPOSITIONS FOR INTRODUCING NUCELIC ACID INTO CELLS - The present invention relates to polymers comprising a characteristic combination of alkylene amine moieties which are useful as vehicles for transfecting a cell with a nucleic acid. The present invention furthermore relates to a composition comprising a nucleic acid and such a polymer, and to a method of transfecting a cell using said composition. Furthermore, the present invention relates to pharmaceutical compositions and uses. | 2018-08-23 |
20180236091 | Pharmaceutical Composition Containing Camptothecin Polymer Derivative - Provided is a pharmaceutical preparation including a polymerized camptothecin derivative that is obtained by bonding a camptothecin derivative having nanoparticle-forming properties by associating in an aqueous solution, to a polymer carrier, the pharmaceutical preparation composition having enhanced preparation stability. Particularly, a pharmaceutical preparation maintaining nanoparticle-forming properties and camptothecin derivative bonding stability, which are important factors, and having excellent storage stability is provided. | 2018-08-23 |
20180236092 | HUMAN INTERFERON-BETA VARIANT CONJUGATED IMMUNOCYTOKINE AND METHOD FOR PREPARING SAME - The present invention relates to an immunocytokine in which a human interferon-beta variant is conjugated to an antibody or a fragment thereof, and a method for preparing the same. The human interferon-beta variant has superior activity or functions compared with natural interferon-beta, and the productivity of the immunocytokine according to the present invention is excellent. In addition, the immunocytokine according to the present invention can be favorably used as a target therapeutic agent for multiple sclerosis or cancer since the immunocytokine express both of functions of the interferon-beta and characteristics of the antibody binding to a specific antigen. | 2018-08-23 |
20180236093 | HERCEPTIN.RTM. ADJUVANT THERAPY - The present application describes adjuvant therapy of nonmetastatic breast cancer using HERCEPTIN®. | 2018-08-23 |
20180236094 | Detection and treatment of malignant tumours in the CNS - The present invention concerns methods of diagnosing and treating a malignant neoplasm of the CNS by detecting mammalian tissue expressing integrin alpha 10 subunit or a fragment or variant thereof, and administering a drug specific for integrin alpha 10 subunit. | 2018-08-23 |
20180236095 | SIALYL-DI-LEWIS A AS EXPRESSED ON GLYCOPROTEINS BUT NOT GLYCOLIPIDS AS A FUNCTIONAL CANCER TARGET AND ANTIBODIES THERETO - The present invention relates to an isolated specific binding member capable of binding sialyl-di-Lewis | 2018-08-23 |
20180236096 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO CD37 PROTEINS - Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer. | 2018-08-23 |
20180236097 | C-MET TARGETING COMPOUND-BIOACTIVE MATERIAL CONJUGATE AND USE THEREOF - Provided is a conjugate including a c-Met targeting compound and a bioactive material and methods of use of the conjugate. | 2018-08-23 |
20180236098 | ALPHA AND GAMMA-D POLYGLUTAMATED ANTIFOLATES AND USES THEREOF - The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with alpha or D-gamma polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and methods of using polyglutamated antifolates and liposome containing formulations to treat hyerproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis). | 2018-08-23 |
20180236099 | SALIPRO PARTICLES - The invention provides a nanoscale particle comprising a lipid binding polypeptide, lipids and a hydrophobic agent, wherein the hydrophobic agent is different from the lipids, and wherein the lipid binding polypeptide is a saposin-like protein or a derivative or truncated form thereof. The invention further provides a process for preparing a particle comprising a saposin-like protein or a derivative or truncated form thereof and lipids comprising the step of (a) contacting the saposin-like protein or a derivative or truncated form thereof with solubilized lipids in a liquid environment and (b) allowing for the self-assembly of the particle at a pH of from 5.0 to 10:0. In addition, pharmaceutical compositions and methods for using the particle of the invention are described. | 2018-08-23 |
20180236100 | CROSS-LINKING AGENTS OF COLLAGEN FIBERS FOR THE USE IN THE TREATMENT OF CORNEAL ECTASIA - It is described a complex of riboflavin into hydroxypropylated β-cyclodextrins as photosensitizer in the riboflavin-UV mediated cross-linking of corneal collage fibers and the relative ophthalmic compositions comprising it. | 2018-08-23 |
20180236101 | THYMIDINE KINASE GENE - Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles. | 2018-08-23 |
20180236102 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION - The present invention relates to a complexed RNA, comprising at least one RNA complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (CPP), has a length of 8 to 15 amino acids and has the empirical formula (Arg) | 2018-08-23 |
20180236103 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HEPATITIS B VIRUS - CRISPR/CAS-related genome editing systems, compositions and methods for preventing and/or treating HBV infection are disclosed. | 2018-08-23 |
20180236104 | EXOSOME TRANSFER OF NUCLEIC ACIDS TO CELLS - Methods for introducing nucleic acids to cells via exosomes for use in gene modulation and therapy, such as for gene silencing and to introduce genetic material into cells to compensate for abnormal genes or to induce or repress a process in the recipient cell. | 2018-08-23 |
20180236105 | METHODS FOR TREATING NEURODEGENERATIVE DISEASES USING GENE THERAPY TO DELAY DISEASE ONSET AND PROGRESSION WHILE PROVIDING COGNITIVE PROTECTION - The present disclosure provides methods of treating a lysosomal storage disorder in a mammal which method comprises administering AAV particles encoding a polypeptide directly to the central nervous system of the mammal in conjunction with administering at least two immunosuppressive agents. AAV particles may be delivered by direct injection into the brain, spinal cord, cerebral spinal fluid or a portion thereof. | 2018-08-23 |
20180236106 | RADIOGRAPHIC NANOPARTICLE CONTRAST AGENTS FOR DUAL-ENERGY X-RAY IMAGING AND COMPUTED TOMOGRAPHY SCANNING AND METHODS OF USING THEREOF - Nanoparticles and nanoprobes for use as a contrast agent for X-ray imaging techniques, CT scanning techniques, MRI and optical imaging are disclosed. The nanoparticles and nanoprobes include a core having a contrast element characterized by a K-edge value ranging from about 17 to about 49 keV, and a stabilizing element which minimizes one or both of cytotoxicity and immunoreactivity of the contrast element. A first coating layer encapsulates the core, the first coating layer configured to render the nanoparticles soluble in a biological medium. A method for dual energy x-ray imaging includes the steps of administering to a subject the nanoparticles disclosed herein as a contrast agent; acquiring an image with a low energy spectrum; and acquiring an image with a high energy spectrum. | 2018-08-23 |
20180236107 | Particle Composition for Use in Medical Imaging and A Method for Preparing Thereof - The present invention relates to a particle composition for use as a contrasting agent in medical imaging such as Magnetic Resonance Imaging (MRI), the particle composition comprising: a metal containing compound comprises at least one metal complexed with at least one metal chelating agent; wherein the metal chelating agent is adapted to bind to one or more protein molecules to thereby allow or enhance visibility of the protein molecules under the medical imaging. The present invention further relates to a diagnostic agent for use in magnetic resonance imaging (MRI) comprising the above described particle composition; and a method of preparing thereof. | 2018-08-23 |
20180236108 | Composition for Use in Medical Imaging and A Method for Preparing Thereof - The present invention relates to a composition for use as a contrast agent in medical imaging. The composition comprises a metal ion containing compound comprises at least one metal ion adapted to bind with one or more metal ion chelating agents; wherein said one or more metal ion chelating agents comprise at least one first chelating agent adapted to target a region of interest being imaged, and at least one second chelating agent having at least one functional group adapted to dissociate in an aqueous medium to thereby allow or enhance contrast of the region of interest under the medical imaging. The present invention further relates to a diagnostic agent for use in amyloid (Aβ) protein detection under magnetic resonance imaging (MRI) comprising the above described composition; and a method of preparing thereof. | 2018-08-23 |
20180236109 | Pain Tracking by PET-imaging (Pain-TraP) - Subject matter of the present invention is PSMA Binding molecules for use in diagnosis and/or imaging of pain. Diagnosis or imaging of pain may be the visualization of the location of the origin of pain and/or the determination of the etiology of pain and/or the determination of the pain intensity and/or the stratification of subjects suffering from pain. | 2018-08-23 |
20180236110 | PSMA-BINDING AGENTS AND USES THEREOF - Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis. | 2018-08-23 |
20180236111 | SMALL MOLECULE IMAGING OF FUNGI BY POSITRON EMISSION TOMOGRAPHY SCANNING - Disclosed herein are isotopically labeled calcofluor derivatives and uses of such to detect fungi, such as filamentous fungi, including | 2018-08-23 |
20180236112 | HOMOMULTIVALENT AND HETEROMULTIVALENT INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND USES THEREOF - The present invention provides bivalent and multivalent ligands with a view to improving the affinity and pharmacokinetic properties of a urea class of PSMA inhibitors. The compounds and their synthesis can be generalized to multivalent compounds of other target antigens. Because they present multiple copies of the pharmacophore, multivalent ligands can bind to receptors with high avidity and affinity, thereby serving as powerful inhibitors. The modular multivalent scaffolds of the present invention, in one or more embodiments, contains a lysine-based (α-, ε-) dialkyne residue for incorporating two or more antigen binding moieties, such as PSMA binding Lys-Glu urea moieties, exploiting click chemistry and one or more additional lysine residues for subsequent modification with an imaging and/or therapeutic nuclides or a cytotoxic ligands for tumor cell killing. | 2018-08-23 |
20180236113 | SELF-SANITIZING WAVEGUIDING SURFACES - A self-sanitizing surface structure configured to selectively refract light, a method of fabricating a self-sanitizing surface configured to selectively refract light, and a method of decontaminating a surface using selectively refracted light. A waveguide including a support layer below a propagating layer is positioned over a substrate as a self-sanitizing layer. In the absence of a contaminant or residue on the waveguide, UV light injected into the propagating layer is constrained within the propagating layer due to total internal reflection. When a residue is present on the self-sanitizing surface structure, light may be selectively refracted at or near the interface with the residue along the side of the waveguide to destroy the residue. The self-sanitizing surface structure may be configured to refract a suitable amount of UV light in response to a particular type of residue or application. | 2018-08-23 |
20180236114 | UV STERILIZATION SYSTEM AND DEVICE AND RELATED METHODS - A UV sterilization device may include a housing defining a cavity therein, and having a door configured to permit access to the cavity, and trays carried within the cavity, each tray configured to receive a mobile wireless communications device. The UV sterilization device may include UV CBAs carried within the cavity respectively adjacent the trays, each UV CBA having LED UV sources configured to irradiate the mobile wireless communications device with UV radiation. The UV sterilization device may include a controller configured to selectively power one or more of the UV CBAs for disinfecting the mobile wireless communications device. | 2018-08-23 |
20180236115 | APPARATUS AND METHOD FOR SANITIZING ARTICLES - An apparatus is provided for sanitizing an article, the apparatus comprising a housing defining an enclosed internal chamber and having an opening at a door side into the chamber. A door is configured to selectively close the door side of the housing for substantially sealing the chamber. A UV light source is disposed internally of the housing for irradiating the chamber, and an electronic circuit is electrically connected to the UV light source and adapted to power the UV light source for a predetermined period of time. A reflector unit is disposed on one of the walls, the reflector unit including a reflective section projecting outwardly at an angle with respect to the wall. With the article placed in the chamber and the door closed and the electronic circuit activated, the UV lamp is illuminated for the predetermined period of time for sanitizing the article. | 2018-08-23 |
20180236116 | METHODS AND APPARATUS FOR TREATMENT OF LUER CONNECTORS - Devices, methods, and systems for a luer connector treatment device are described herein. The luer connector treatment device may include one or multiple sources of UV radiation configured to emit UV radiation capable of sterilizing the contents of a treatment chamber while a first medical device (e.g., catheter) is connected to a secondary medical device, and while the first medical device is separate from a secondary medical device. Sources of UV radiation may be located along both a cap and body of the luer connector treatment device. | 2018-08-23 |
20180236117 | METHOD AND APPARATUS FOR DISINFECTING INNER SURFACES OF FREEZERS - A method and a device for disinfecting inner surfaces, for example, of freezers and the like includes the production of a microfilm of sanitizing solution on the inner surfaces and on the devices contained in the freezers and the like, by a method which comprises two sequential steps, a first step in which 100% of the inner surface of the internal environment of the freezer or the like is completely saturated with a mist of sanitizing solution, which is then condensed, and a second step in which the air containing this mist is passed through a filter provided with means that absorb the sanitizing solution, both steps being implemented by closed-loop recirculation means (looping). | 2018-08-23 |
20180236118 | SILVER NANOPARTICLES IMPREGNATED COVERS FOR ELECTRONIC DEVICES TO COMBAT NOSOCOMIAL INFECTIONS - An anti-microbial covering for use with electronic devices used in a hospital environment is disclosed. A flexible thermoplastic sheet is impregnated during manufacturing with nano-sized sliver particles and wrapped around the electronic device to stop the spread of nosocomial infections. The silver particles vary in shape and size to maximize the anti-microbial effects of each sheet, and each particle is sized to be less than 60 nanometers in diameter. The present invention includes a process for producing each sheet by combining low density polyethylene, linear low density polyethylene, polyphthalamide and other additives with sliver nanoparticles, and then extruding the thermoplastic mixture under heat to form thin impregnated sheets. The liner sheets may then be die-cut to form shaped perforations to facilitate the shaping of each sheet around a targeted electronic device, and cut into convenient sizes for dispensing. | 2018-08-23 |
20180236119 | WEARABLE FRAGRANCE EMISSION DEVICE - A method and apparatus are provided to determine a pattern of emitting scents uniquely tailored to a particular user. A wearable fragrance emission device may store a fragrance emission pattern which correlates particular conditions with scents to be emitted from the device. The device detects conditions, such as environmental conditions or conditions related to the user, and periodically emits one or more fragrances in response to detected conditions. The wearable fragrance emission device may include one or more sensors for detecting the conditions. | 2018-08-23 |
20180236120 | NONLEAKING VOLATILE SUBSTANCE DELIVERY SYSTEM - A volatile substance delivery system includes a volatile substance container to contain a volatile substance, an optional absorbent and collapsible element disposed within the container to reduce presence of undesired air during manufacture of the device, an outlet to deliver a volume of the volatile substance from the volatile substance container toward an ambient environment, and a manual screw pump to reduce volume (or sometimes, just increase pressure) within the volatile substance container and promote the delivery of the volatile substance from the volatile substance container. A safety chamber is sometimes provided to resist unintended escape of volatile substance in liquid phase to the environment. | 2018-08-23 |
20180236121 | PURIFIED AIR AND METHODS OF MAKING AND USING THE SAME - Purified air is provided, having a TVOC content of from less than 5 ppb to about 500 ppb, a Biologicals content of from less than 1 CFU/M | 2018-08-23 |
20180236122 | POLYMER METAL-ORGANIC FRAMEWORK COMPOSITES - Provided herein are polymer and metal organic frameworks (MOFs) composites, and methods of use and preparation thereof. In particular, Poly(polyethyleneglycol citrate-co-N-isopropylacrylamide) (PPCN) and copper MOF composites are provided. | 2018-08-23 |
20180236123 | Hemostatic Composition and Hemostatic Device (Variants) - The hemostatic composition, comprising water-retaining, binder dust suppression, inorganic and organic hemostatic agents, and hemostatic device comprising the composition of hemostatic agents and a container that keeps hemostatic composition. | 2018-08-23 |
20180236124 | HYDROGEL COMPOSITIONS BONDED TO POLYMERIC SUBSTRATES - Described herein is a multilayer article comprising: a. a polymer substrate comprising an abstractable atom; and b. a hydrogel coating thereon wherein the hydrogel coating has a water content of at least 10 wt % and is covalently bonded to the polymer substrate, and wherein the hydrogel coating is derived from an aqueous composition having a pH less than 9.5, the aqueous composition comprising: (a) a hydrophilic monomer selected from at least one of (meth)acrylate or (meth)acrylamide; (b) at least 0.1 wt % of a water-swellable clay; (c) a first initiator, wherein the first initiator is water-soluble and is a Type I photoinitiator; and (d) a second initiator, wherein the initiator is water-soluble and is a Type II photoinitiator; and (e) an acid. | 2018-08-23 |
20180236125 | ABSORBABLE COMPOSITIONS AND METHODS FOR THEIR USE IN HEMOSTASIS - The present invention is direct to a body-absorbable, mechanically hemostatic composition comprising a solid poloxamer having an average molecular weight of about 7,000 g/mol to about 15,000 g/mol, a high molecular weight dextran, optionally a fatty acid salt, and water, and a method for mechanically controlling the bleeding of bone comprising applying an effective amount of the composition to the affected area. | 2018-08-23 |
20180236126 | DISSOLVABLE NASAL SINUS SPONGE - An implantable article comprising a dissolvable sponge derived from the mixture of chitosan, a first polysaccharide and a second polysaccharides. The polysaccharides have different number average molecular weight characteristics to enable the control of the mechanical features of the sponge. | 2018-08-23 |
20180236127 | DEVICES FOR AND METHODS OF TREATMENT OF METABOLIC SYNDROMES - Devices for and methods of treatment of metabolic syndromes are disclosed. Namely, the presently disclosed devices and methods are provided for affecting the function of the gastrointestinal endocrine system in key regions of the gut, thereby, producing therapeutic effects on obesity, diabetes and other metabolic syndromes. In some embodiments, the devices include multilayered bioadhesive patches delivered orally by dissolvable ingestible capsule, wherein various mechanisms are provided for anchoring the bioadhesive patches to the duodenal mucosa. | 2018-08-23 |
20180236128 | IMPLANT-BASED REPAIR OF OSTEOCHONDRAL DEFECTS - The present invention is directed to a unique technology for preparing a growth-factor free, cylindrical, hydrogel implant that has multiple (three or more) longitudinal hydrogel zones with varying chemical and physical properties. The implant may be wholly made of hydrogels or the hydrogels may be associated with cells, such as mesenchymal stem cells (MSCs). | 2018-08-23 |
20180236129 | IMPLANTS FOR SCULPTING, AUGMENTING OR CORRECTING FACIAL FEATURES SUCH AS THE CHIN - An injectable device, comprising a hyaluronic acid-based composition, useful for long lasting facial sculpting and correction of facial features, for example, for augmenting and shaping the profile, including for example, the chin, jawline or the nose, in a human being is provided. Methods of treatment are also provided. | 2018-08-23 |
20180236130 | AMELOGENIN-CHITOSAN HYDROGEL FOR DENTIN HYPERSENSITIVITY - A method to regrow a protective layer over exposed/demineralized dentin that includes a step of identifying a subject having exposed/demineralized dentin. The demineralized dentin is contacted with a remineralization composition that includes an amelogenin and derived peptides, a chitosan, water, and a sufficient amount of a pH adjusting component such that the composition has a pH greater than about 6.0 such that dentinal tubules are occluded with apatite crystals and enamel is regrown on the dentinal tubules. | 2018-08-23 |
20180236131 | BIOSCAFFOLDS FOR FORMATION OF MOTOR ENDPLATES AND OTHER SPECIALIZED TISSUE STRUCTURES - Provided herein are scaffolds and methods useful to promote the formation of functional clusters on a tissue, for example, motor endplates (MEPs) or a component thereof on skeletal muscle cells or tissue, as well as the use of scaffolds so produced for repairing a tissue injury or defect. | 2018-08-23 |
20180236132 | MATERIAL FOR BONE IMPLANTS AND METHOD OF PRODUCING SAME - The present invention relates to a material for bone implants, comprising: a surface of oxidic ceramic materials, titanium or polyether ether ketone (PEEK) or other polymer or composite materials, a matrix of collagen or gelatin, which is covalently bound to said surface, and calcium phosphate embedded into said matrix. The present invention further relates to a method for producing the material according to the invention, to bone implants comprising the material according to the invention, and to its use as a bone implant material. | 2018-08-23 |
20180236133 | METHODS OF PRODUCING EXTRACELLULAR MATRIX USEABLE IN BREAST IMPLANT SURGERY AND OTHER MATRIX PRODUCTION - Methodologies in which GAG/collagen mixtures are homogenized into slurries, lyophilized, and dried, have been producing solid matrix products that have favorable tackiness for use in breast reconstruction surgery. | 2018-08-23 |
20180236134 | SYSTEMS FOR AND METHODS FOR USING BIOMIMETIC STRUCTURES PROVIDING COMMUNICATION IN LIVING TISSUE - A platform for creating engineered tissues includes a vascular tube that defines a vascular diameter and is configured to receive vascular system seed cells, a non vascular tube that defines a non-vascular tube diameter and is configured to receive organ system seed cells, and a barrier formed between the vascular tube and the non vascular tube. | 2018-08-23 |
20180236135 | METHODS AND COMPOSITIONS RELATING TO BIOCOMPATIBLE IMPLANTS - Biocompatible hydrogel compositions according to aspects of the present invention are provided wherein the biocompatible hydrogel composition is or includes a physical hydrogel, a chemical hydrogel or both a physical hydrogel and a chemical hydrogel, along with biocompatible hydrogel compositions encapsulating a therapeutic agent and methods of use thereof. | 2018-08-23 |
20180236136 | INTERPENETRATING POLYMER NETWORKS - IPN compositions and methods of making the same are provided. The IPN compositions can include a water swellable, water permeable IPN or semi-IPN member with a first polymer network including a hydrophobic thermoset or thermoplastic polymer, a second polymer network including a non-ionic polymer, and a third polymer network including an ionic polymer containing sulfonic acid functional groups that are otherwise difficult to form composites with hydrophobic polymers. The IPN compositions can be used in orthopedic implants or in mechanical applications as a bearing material. | 2018-08-23 |
20180236137 | Hierarchical porous material - A hierarchical porous material consists of multistage porous materials, comprising a material body, the body is formed bar a pore cavity graded according to the pore size of the material and a cavity wall surrounding to form the pore cavity. The pore cavities are uniformly distributed. The characteristics are as follows. A lower-level pore cavities are disposed on the cavity wall of an upper-level pore cavity formed by surrounding a three-dimensional space. Each level of pore cavities are mutually connected and the pore cavities within same level are also connected with each other. The uniform distribution of the pore cavities means that similar amount of pore cavities are distributed under any unit volume of the hierarchical porous material. The hierarchical structure of the cavity of the material enables it to meet a wide range of functional requirements. | 2018-08-23 |
20180236138 | Porous Material and Preparation Method Thereof - A porous material and preparation method thereof is provided. The material includes a material body. The body consists of pore cavities classified according to pore size of material and cavity walls surrounding to form the pore cavities. The lower-level pore cavities are arranged on the cavity walls of the upper-level pore cavities framed by surrounding a three-dimensional space. All the pore cavities are interconnected. The preparation method is: mixing raw powders with pore-forming agent for the smallest-level pore cavities of porous material to formulate slurry; uniformly filling the slurry into polymer material support to form green body and get dried and smashed to obtain mixed grains; uniformly mixing the mixed grains with pore-forming agent for upper-level pore cavities greater than the smallest-level pore cavities of porous material to make compact green body; performing vacuum sintering; performing the conventional follow-up treatment according to the raw materials process of porous material. | 2018-08-23 |
20180236139 | DRUG COATED MEDICAL DEVICES - A medical device includes a body defining an exterior surface, and a coating including a therapeutic agent-containing nanoparticle disposed on the exterior surface of the medical device. The nanoparticle may include a brush-arm star polymer. The therapeutic agent may be paclitaxel. | 2018-08-23 |
20180236140 | HYDROPHOBICALLY ENCASED TUNGSTEN - Disclosed herein are compositions of matter for inclusion in a medical device for visualization purposes. Such compositions may include a radiopaque metal, such as tungsten, within a functionalized hydrophobic polymer. Methods of making devices incorporating such elements are also disclosed. | 2018-08-23 |